Lipids in the Wrong Place: Visceral Fat and Nonalcoholic Steatohepatitis
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
There is substantial evidence in both animal (1,2) and human models of lipodystrophy (3) that the accumulation of excessive fat in ectopic sites that normally lack adipose tissue, such as the skeletal muscle and the liver, may trigger whole-body insulin resistance. This article will review the evidence showing the condition of fatty liver as an independent and perhaps better indicator of disease than excessive accumulation of visceral adipose tissue. On the basis of the hypothesis that a fatty liver may increase the risk of cardiovascular disease (CVD), this article will not only focus on the metabolic-related features, but also on the cardiovascular risk factors affecting individuals with fatty liver. The biomarkers of CVD will therefore be analyzed in patients with fatty livers. Finally, epidemiological evidence linking fatty liver to the development of type 2 diabetes and CVD will be given. ### Metabolic features of individuals with insulin impairment: what contributes more, fatty liver or visceral adipose tissue? Nonalcoholic fatty liver disease (NAFLD) is often found together with insulin resistance syndrome (4,5) and is commonly found in those suffering from visceral adiposity (3,4). Multiple insulin-related metabolic abnormalities in both organs and tissues have been reported, including impaired insulin-mediated inhibition of hepatic glucose production in livers (4–8), impaired insulin-stimulated glucose metabolism in skeletal muscle tissue (4–9), and impaired insulin-dependent control of lipolysis in adipose tissue (4–10). These metabolic abnormalities are often present along with the increased visceral adipose tissue and a fatty liver. It is very difficult to determine the biological relevance of each anthropometric feature because they are so commonly found together in humans. Recent studies have shown that of these two indicators, i.e., intrahepatic fat content (IHF) and excess visceral adipose tissue, IHF is statistically a more relevant indicator than excess visceral adipose tissue. In insulin-treated type 2 diabetic patients, the IHF content was more …
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonalcoholic Fatty Liver Disease
Marchesini, G., Brizi, M., Bianchi, G., Tomassetti, S., Bugianesi, E., Lenzi, M., McCullough, A. J., Natale, S., Forlani, G., & Melchionda, N. (2001) · Diabetes · doi:10.2337/diabetes.50.8.1844 · Cited by 2,581 · cited 1×
“Metabolic features of individuals with insulin impairment: what contributes more, fatty liver or visceral adipose tissue? Nonalcoholic fatty liver disease (NAFLD) is often found together with insulin resistance syndrome (4,5) and is commonly found in those suffering from visceral adiposity (3,4).”
BackgroundRisk of Cardiovascular Disease in Patients with Nonalcoholic Fatty Liver Disease
Targher, G., Day, C. P., & Bonora, E. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0912063 · Cited by 1,907
Identification and characterization of metabolically benign obesity in humans
Stefan, N. (2008) · Archives of Internal Medicine · doi:10.1001/archinte.168.15.1609 · Cited by 1,049
Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy
Petersen, K. F., Oral, E. A., Dufour, S., Befroy, D., Ariyan, C., Yu, C., Cline, G. W., DePaoli, A. M., Taylor, S. I., Gorden, P., et al. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215001 · Cited by 800 · cited 2×
“There is substantial evidence in both animal (1,2) and human models of lipodystrophy (3) that the accumulation of excessive fat in ectopic sites that normally lack adipose tissue, such as the skeletal muscle and the liver, may trigger whole-body insulin resistance.”
BackgroundBugianesi, E., Gastaldelli, A., Vanni, E., Gambino, R., Cassader, M., Baldi, S., Ponti, V., Pagano, G., Ferrannini, E., & Rizzetto, M. (2005) · Diabetologia · doi:10.1007/s00125-005-1682-x · Cited by 770
Gastaldelli, A., Cusi, K., Pettiti, M., Hardies, J., Miyazaki, Y., Berria, R., Buzzigoli, E., Sironi, A. M., Cersosimo, E., Ferrannini, E., et al. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.04.068 · Cited by 629 · cited 1×
“Similar conclusions were also reported in individuals with overt type 2 diabetes (7).”
ResultMechanism of Insulin Resistance in A-ZIP/F-1 Fatless Mice
Kim, J. K., Gavrilova, O., Chen, Y., Reitman, M. L., & Shulman, G. I. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.12.8456 · Cited by 443 · cited 1×
“There is substantial evidence in both animal (1,2) and human models of lipodystrophy (3) that the accumulation of excessive fat in ectopic sites that normally lack adipose tissue, such as the skeletal muscle and the liver, may trigger whole-body insulin resistance.”
BackgroundRyysy, L., Häkkinen, A. M., Goto, T., Vehkavaara, S., Westerbacka, J., Halavaara, J., & Yki-Järvinen, H. (2000) · Diabetes · doi:10.2337/diabetes.49.5.749 · Cited by 431 · cited 1×
“In insulin-treated type 2 diabetic patients, the IHF content was more closely correlated with the insulin dose and the sensitivity of endogenous (hepatic) glucose production to insulin and better explained the interindividual variation in insulin requirements (11).”
BackgroundApolipoprotein C3 gene variants in nonalcoholic fatty liver disease
Petersen, K. F., Dufour, S., Hariri, A., Nelson-Williams, C., Foo, J. N., Zhang, X.-M., Dziura, J., Lifton, R. P., & Shulman, G. I. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907295 · Cited by 428
Kelley, D. E., McKolanis, T. M., Hegazi, R. A. F., Kuller, L. H., & Kalhan, S. C. (2003) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00117.2003 · Cited by 426
Cited by
MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease
Eslam, M., Sanyal, A. J., George, J., Sanyal, A., Neuschwander-Tetri, B., Tiribelli, C., Kleiner, D. E., Brunt, E., Bugianesi, E., Yki-Järvinen, H., et al. (2020) · Gastroenterology · doi:10.1053/j.gastro.2019.11.312 · Cited by 3,286
The worldwide epidemiology of type 2 diabetes mellitus—present and future perspectives
Chen, L., Magliano, D. J., & Zimmet, P. Z. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.183 · Cited by 2,227
Chamorro-García, R., Sahu, M., Abbey, R. J., Laude, J., Pham, N., & Blumberg, B. (2013) · Environmental Health Perspectives · doi:10.1289/ehp.1205701 · Cited by 331
Mavros, Y., Kay, S., Anderberg, K. A., Baker, M. K., Wang, Y., Zhao, R., Meiklejohn, J., Climstein, M., O’Sullivan, A., de Vos, N., et al. (2013) · Diabetes Care · doi:10.2337/dc12-2196 · Cited by 118
Cordero, P., Milagro, F. I., Campion, J., & Martinez, J. A. (2014) · Journal of Developmental Origins of Health and Disease · doi:10.1017/s204017441400035x · Cited by 45
“Thus, it could be hypothesized that the excess of fat that has not been ectopically stored in the liver, has been accumulated in the body’s natural storage site, mainly in the visceral adipose depots.(32) In this way, Fabbrini et al.”
Background
Metadata
- Authors
- Perseghin, G.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2011-04-22
- Volume
- 34
- Issue
- Supplement_2
- Pages
- S367-S370
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2140853326
- Cited by
- 43
- References
- 14
- FWCI
- 3.67
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Lipids in the Wrong Place: Visceral Fat and Nonalcoholic Steatohepatitis. https://app.cochat.ai/papers/10.2337/dc11-s249
- The paper
- Perseghin, G. (2011). Lipids in the Wrong Place: Visceral Fat and Nonalcoholic Steatohepatitis. Diabetes Care. https://doi.org/10.2337/dc11-s249
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.